145 related articles for article (PubMed ID: 29183231)
21. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
22. Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties.
Zahid H; Tayara H; Chong KT
Arch Toxicol; 2024 Apr; ():. PubMed ID: 38619593
[TBL] [Abstract][Full Text] [Related]
23. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
24. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9.
Goldwaser E; Laurent C; Lagarde N; Fabrega S; Nay L; Villoutreix BO; Jelsch C; Nicot AB; Loriot MA; Miteva MA
PLoS Comput Biol; 2022 Jan; 18(1):e1009820. PubMed ID: 35081108
[TBL] [Abstract][Full Text] [Related]
25. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
Yang X; Atkinson K; Di L
Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
[TBL] [Abstract][Full Text] [Related]
26. Large-scale evaluation of cytochrome P450 2C9 mediated drug interaction potential with machine learning-based consensus modeling.
Rácz A; Keserű GM
J Comput Aided Mol Des; 2020 Aug; 34(8):831-839. PubMed ID: 32221780
[TBL] [Abstract][Full Text] [Related]
27. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
[TBL] [Abstract][Full Text] [Related]
28. Survey of Machine Learning Techniques for Prediction of the Isoform Specificity of Cytochrome P450 Substrates.
Xiong Y; Qiao Y; Kihara D; Zhang HY; Zhu X; Wei DQ
Curr Drug Metab; 2019 May; 20(3):229-235. PubMed ID: 30338736
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes.
Lang J; Li W; Zhao J; Wang K; Chen D
Xenobiotica; 2017 Oct; 47(10):849-855. PubMed ID: 27819189
[TBL] [Abstract][Full Text] [Related]
30. In Silico Predictions of Drug - Drug Interactions Caused by CYP1A2, 2C9 and 3A4 Inhibition - a Comparative Study of Virtual Screening Performance.
Kaserer T; Höferl M; Müller K; Elmer S; Ganzera M; Jäger W; Schuster D
Mol Inform; 2015 Jun; 34(6-7):431-57. PubMed ID: 27490388
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.
Nielsen LM; Holm NB; Olsen L; Linnet K
Drug Test Anal; 2016 Aug; 8(8):792-800. PubMed ID: 26360322
[TBL] [Abstract][Full Text] [Related]
32. Prediction of selective estrogen receptor beta agonist using open data and machine learning approach.
Niu AQ; Xie LJ; Wang H; Zhu B; Wang SQ
Drug Des Devel Ther; 2016; 10():2323-31. PubMed ID: 27486309
[TBL] [Abstract][Full Text] [Related]
33. Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs.
Beck TC; Beck KR; Morningstar J; Benjamin MM; Norris RA
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34067565
[TBL] [Abstract][Full Text] [Related]
34. Classification of cytochrome p(450) activities using machine learning methods.
Hammann F; Gutmann H; Baumann U; Helma C; Drewe J
Mol Pharm; 2009; 6(6):1920-6. PubMed ID: 19813762
[TBL] [Abstract][Full Text] [Related]
35. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
[TBL] [Abstract][Full Text] [Related]
36. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
37. ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates.
Li D; Chen L; Li Y; Tian S; Sun H; Hou T
Mol Pharm; 2014 Mar; 11(3):716-26. PubMed ID: 24499501
[TBL] [Abstract][Full Text] [Related]
38. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
39. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates.
Terfloth L; Bienfait B; Gasteiger J
J Chem Inf Model; 2007; 47(4):1688-701. PubMed ID: 17608404
[TBL] [Abstract][Full Text] [Related]
40. Novel Electrotopological Atomic Descriptors for the Prediction of Xenobiotic Cytochrome P450 Reactions.
Kaitoh K; Kotera M; Funatsu K
Mol Inform; 2019 Oct; 38(10):e1900010. PubMed ID: 31187601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
